Areas of Excellence

 
 
 
  • ONCOLOGY
    The Comprehensive Oncology Centre offers comprehensive and multidisciplinary cancer management to patients. The Centre comprises a team of medical specialists and professional nurses, is equipped with high-end medical technologies, e.g. image-guided biopsy, Dual Tracer PET/CT (F-18-FDG and C-11-Acetate), TomoTherapy and M6 CyberKnife and endeavours to provide quality clinical diagnosis and the most suitable treatment in various modalities, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy and autologous peripheral blood stem cell transplantation. Supporting services of professional patient counselling, psychological support, pain management, physical fitness and dietary advices are also available.
  • Radiotherapy
  • Chemotherapy
  • Targeted Therapy
    Molecular targeted agents are currently the focus of active cancer research. With better understanding of the molecular mechanisms of tumorogenesis of various cancers, drugs can be developed to interfere with specific molecular targets that are involved in the growth and spread of cancer.

    For a specific targeted therapy to work, the corresponding molecular target must be present in the tumor cell, and this is usually verified by tumor biopsy or blood test. The drugs are either in the form of small molecular oral inhibitor or monoclonal antibody given intravenously. They target at different levels of signal transduction pathway that control cell proliferation, cell death, tumor microenvironment, and tumor blood supply. In contrast to chemotherapy which makes no distinction between normal and cancer cells in its attack, targeted therapy causes less damage to normal cells and is therefore associated with less treatment side effects.

    Many different targeted therapies have been approved for use either as monotherapy or in combination with chemotherapy. A wide variety of targeted drugs have been approved for the treatment of leukaemia, lymphoma and multiple myeloma. To name a few, chimeric antigen receptor T-cell (CAR-T) therapy genetically modulates autologous T cell to target specific tumor antigen, and is currently used in relapsed leukaemia and lymphoma.

    Mabther/Rituximab is a monoclonal antibody commonly used to treat all kinds of B-cell lymphomas. Imatinib is a protein kinase small molecular inhibitor that is effective in treating chronic myeloid leukaemia.

    A proportion of lung cancers harbor specific driver mutation, such as the EGFR mutation, ALK rearrangement, ROS1 rearrangement, and BRAF V600E mutation. Specific Tyrosine Kinase Inhibitors, such as Erlotinib, Gefinitib, Afatinib, Decomitinib and Osimertinib are popular drugs used to treat EGFR mutated lung cancers.

    Targeted therapy is also widely used in breast cancer. Breast cancer can be classified into three distinct phenotypes: Hormone receptor positive type, HER-2 positive type, and Triple negative type. Cyclin-D kinase 4/6 inhibitors and mTOR inhibitors have been approved for use in combination with hormone therapy to overcome endocrine resistance in hormone receptor positive tumor. Anti-HER2 antibody (Herceptin and Pertuzumab) and HER2 antibody-drug conjugate (TDM-1) are monoclonal antibodies that are effective in HER2 positive disease. Polyadenosine Diphosphoribose Polymerase (PARP) inhibitor (Olaparib) has been approved for use in triple negative breast cancer with germline BRCA mutation.

    A number of drugs that inhibit multiple receptor tyrosine kinases have been established as the standard of care treatment in advanced kidney (Cabozantinib, Sunitinib, Pazopanib, Axitinib, Lenvatinib, Sorafenib) and liver cancer (Sorafenib, Lenvatinib, Regorafenib).

    Antibody against the vascular endothelial growth factor (VEGF) or VEGF-receptor (VEGFR) has been developed to inhibit vascular growth in tumor. Bevacizumab, an anti-VEGF antibody, has been widely used in colorectal cancer, cervical cancer, glioblastoma (a type of brain tumor), lung cancer, ovarian cancer and kidney cancer. Ramucirumab is an anti-VEGFR antibody that is approved for use in stomach cancer, colorectal cancer, and lung cancer.

    Epidermal growth factor receptors (EGFR) are over-expressed in colorectal cancer and head and neck squamous cell carcinoma. Cetuximab and Panitumumab are anti-EGFR antibodies used to treat these types of cancers.
  • Immunotherapy
  • Hormone Therapy